Stanford Medicine
Avatar

COVID-19 & Strategies to Improve Care for High-Risk Patients With Type 2 Diabetes: What Are the Top 5 Most Effective Interventions? How Can We Implement the ASCVD Risk Calculator Success Tactics?

By Stanford Medicine FEATURING John W. Kennedy
By Stanford Medicine FEATURING John W. Kennedy
34 views
August 25, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

62:17
HeartFlow

Chest Pain in Women: CT's role in making an accurate diagnosis

Feat. L. Shaw, M. Gulati

Related Content

AUTOPLAY
12:04
Stephen Kopecky

Role of PCSK9 Inhibitors in Diabetes

28:13
National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

Feat. R. Mason
26:32
Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen
19:20
National Lipid Association

Colchicine: Now and What’s Next?

Feat. C. Ballantyne
22:14
Practical Ways to Achieve Targets in Diabetes Care

Role of Lipoprotein (a) in Coronary Disease: An Emerging Novel Target

Feat. S. Nissen
21:10
National Lipid Association

Plant-based Diets for Improving Lipids

Feat. K. Williams
11:26
Houston Methodist DeBakey Heart and Vascular Center

Aspirin for the Primary Prevention of Cardiovascular Disease: What C…

Feat. M. Miedema
11:50
American Heart & Vascular Institute

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

Feat. M. Kittleson
29:04
15th Annual Orange County Symposium for Cardiovascular Disease Prevention

LDL-C: Earlier and Lower Is Better and Safer?

Feat. P. Rosenblit
30:00
Piedmont Heart Institute

Cardiometabolic Therapies: GLP-1 RAs and SGLT-2i

Feat. J. Burkle
25:54
13th Orange County Symposium for Cardiovascular Disease Prevention

SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Whic…

Feat. Y. Handelsman
62:08
University of Louisville

Update on Coronary Revascularization

Feat. S. Ghafghazi
24:45
National Lipid Association

Cardiovascular Disease in Patients with HIV

Feat. W. R. Short
67:29
Philips

Step Ahead - PAD & CLI State of the Art and the COVID 19 Era Imp…

Feat. C. Walker, C. Lesar, S. Madassery, T. Yates
18:42
Cardiometabolic Health Congress (CMHC)

ASCVD Risk Assessment and Prevention: Where Do We Stand Now?

Feat. S. Virani
18:02
13th Orange County Symposium for Cardiovascular Disease Prevention

The Gut Microbiome: Friend or Foe?

Feat. R. Greenfield
25:22
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

The Effect of Cancer Therapies on Diabetes

Feat. E. Gallagher
20:56
Stanford Medicine

COVID-19 & Diabetes Treatment: Can We Reduce the Risk of Poorer …

Feat. A. Peters
27:23
American Heart & Vascular Institute

Novel Therapies in Heart Failure: What Are the Indications and Contr…

Feat. L. Kemeyou
22:20
Cedars Sinai

What Diet Is Best for Cardiovascular Health?

Feat. K. Williams